• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Verastem Inc.

    5/29/26 4:40:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    S-8 1 tm2615776d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 29, 2026

    Registration No. 333-    

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Verastem, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   27-3269467
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer Identification No.)
         
    117 Kendrick Street, Suite 500
    Needham, MA
      02494
    (Address of Principal Executive Offices)   (Zip Code)

     

    2014 Inducement Award Program
    Amended and Restated 2021 Equity Incentive Plan
    Amended and Restated 2018 Employee Stock Purchase Plan
    (Full title of the plan)

     

    Daniel Paterson
    President and Chief Executive Officer
    Verastem, Inc.
    117 Kendrick St., Suite 500
    Needham, MA 02494
    (781) 292-4200

    (Name, address, and telephone number, including area code, of agent for service)

     

    With copies to:
    Marko S. Zatylny
    Ropes & Gray LLP
    Prudential Tower
    800 Boylston Street
    Boston, MA 02199
    (617) 951-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed to register (i) an additional 5,000,000 shares under the Registrant’s Amended and Restated 2018 Employee Stock Purchase Plan, (ii) an additional 12,000,000 shares under the Registrant’s Amended and Restated 2021 Equity Incentive Plan and (iii) an additional 600,000 shares under the Registrant’s 2014 Inducement Award Program. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statements on Form S-8 (File Nos. 333-201075, 333-218768, 333-223616, 333-228309, 333-229430, 333-257111, 333-277948, 333-279826 and 333-291253) filed with the Securities and Exchange Commission on December 19, 2014, June 15, 2017, March 13, 2018, November 9, 2018,  January 30, 2019, June 15, 2021, March 14, 2024, May 30, 2024 and November 4, 2025, respectively.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit   Description
    4.1   Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
    4.2   Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
    4.3   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 21, 2020)
    4.4   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 31, 2023)
    4.5   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 to Amendment No. 3 to the Registration Statement on Form S-1 filed by the Registrant with the Securities and Exchange Commission on January 13, 2012)
    4.6   Form of Inducement Award Nonstatutory Stock Option Agreement (incorporated by reference to Exhibit 10.11 of the Registrant’s Annual Report on Form 10-K filed by the Registrant on March 13, 2018)
    4.7   Form of Inducement Award Restricted Stock Unit Agreement (incorporated by reference to Exhibit 4.3 of the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed by the Registrant with the Securities and Exchange Commission on November 7, 2018)
    4.8   Form of Nonstatutory Stock Option Agreement (Non-Employees) under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.9   Form of Inducement Nonstatutory Stock Option Agreement (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)
    4.10   Form of Inducement Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant on May 7, 2020)
    4.11   Form of Inducement Nonstatutory Stock Option Agreement (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.12   Form of Inducement Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.13   Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A, filed by the Registrant with the Securities and Exchange Commission on April 9, 2026)
    4.14   Form of Incentive Stock Option Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.15   Form of Nonstatutory Stock Option Agreement (Employees) under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.16   Form of Restricted Stock Unit Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q filed by the Registrant on August 2, 2021)
    4.17   Form of Restricted Stock Unit Agreement under the Amended and Restated 2021 Equity Incentive Plan. (incorporated by reference to Exhibit 10.45 on Form 10-K filed by the Registrant with the Securities and Exchange Commission on March 20, 2025).
    4.18   Amended and Restated 2018 Employee Stock Purchase Plan. (incorporated by reference to Appendix B of the Registrant’s Definitive Proxy Statement on Schedule 14A, filed by the Registrant with the Securities and Exchange Commission on April 9, 2026)
    5.1   Opinion of Ropes & Gray LLP (filed herewith)
    23.1   Consent of Ropes & Gray LLP (included in Exhibit 5.1)
    23.2   Consent of Ernst & Young LLP (filed herewith)
    24.1   Power of attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney”)
    107   Filing Fee Table (filed herewith)

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Needham, Commonwealth of Massachusetts on May 29, 2026.

     

      VERASTEM, INC.
         
      By: /s/ Daniel Paterson
        Daniel Paterson
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Daniel Paterson and Daniel Calkins, and each of them singly, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    SIGNATURES   TITLE   DATE
    /s/ Daniel Paterson   President, Chief Executive Officer and Director   May 29, 2026
    Daniel Paterson   (Principal executive officer)    
             
    /s/ Daniel Calkins   Chief Financial Officer   May 29, 2026
    Daniel Calkins   (Principal financial and accounting officer)    
             
    /s/ Michael P. Bailey   Director   May 29, 2026
    Michael P. Bailey        
             
    /s/ Paul A. Bunn, M.D.   Director   May 29, 2026
    Paul A. Bunn, M.D.        
             
     /s/ John H. Johnson   Director   May 29, 2026
    John H. Johnson        
             
    /s/ Anil Kapur   Director   May 29, 2026
    Anil Kapur        
             
    /s/ Michael Kauffman   Director   May 29, 2026
    Michael Kauffman, M.D., Ph.D.        
             
    /s/ Michelle Robertson   Director   May 29, 2026
    Michelle Robertson        
             
    /s/ Eric Rowinsky, M.D.   Director   May 29, 2026
    Eric Rowinsky, M.D.        
             
    /s/ Brian Stuglik   Director   May 29, 2026
    Brian Stuglik        
             
    /s/ Karin Tollefson   Director   May 29, 2026
    Karin Tollefson        

     

     

    Get the next $VSTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    3/12/2026$19.00Buy
    BTIG Research
    2/4/2026$18.00Buy
    H.C. Wainwright
    10/16/2025Overweight
    Cantor Fitzgerald
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    More analyst ratings

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Michael P was granted 108,000 shares (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    5/27/26 5:45:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bailey Michael P

    3 - Verastem, Inc. (0001526119) (Issuer)

    5/27/26 5:44:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tollefson Karin Anna was granted 36,000 shares, increasing direct ownership by 216% to 52,666 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    5/26/26 6:23:36 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC) FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas

    6/3/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Present at Jefferies Healthcare Conference

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and

    5/27/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. "We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX®," said Daniel Paterson, pre

    5/26/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research resumed coverage on Verastem with a new price target

    BTIG Research resumed coverage of Verastem with a rating of Buy and set a new price target of $19.00

    3/12/26 8:55:19 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    SEC Filings

    View All

    SEC Form S-8 filed by Verastem Inc.

    S-8 - Verastem, Inc. (0001526119) (Filer)

    5/29/26 4:40:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Verastem Inc.

    144 - Verastem, Inc. (0001526119) (Subject)

    5/27/26 4:47:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Verastem, Inc. (0001526119) (Filer)

    5/26/26 8:15:11 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/24/24 4:00:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    View All

    Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. "We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceutical and biotechnology companies, with a proven track record of taking oncology medicines from clinical development through successful commercialization, including landmark therapies like ERBITUX®," said Daniel Paterson, pre

    5/26/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    3/20/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Financials

    Live finance-specific insights

    View All

    Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

    AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth Initiated Phase 2 registration-directed trials "VS-7375 TARGET-D Clinical Program" in 2L PDAC, 2L/3L NSCLC and 2L+ CRC VS-7375 TARGET-D 101 early data update expected in the first half of 2026; mature data update expected in the second half of 2026 Ended Q1 2026 with $181.7 million in cash, cash equivalents and investments; expected cash runway into first half of 2027 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medic

    5/7/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical

    4/23/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's websit

    2/18/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verastem Inc.

    SC 13G - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care